Assessing Chubb (CB) Valuation After Solid Multi‑Year Returns And Mixed Growth Figures

Advertisement

Recent share performance and business mix

Chubb (CB) has seen a small daily move of 0.04% and a 5.2% gain year to date, with the stock closing at US$326.27. Over the past year the total return is 12.5%.

Returns over the past week and month are 4.7% and 1.4%, while performance over the past 3 months is slightly lower, down 0.5%. For longer term holders, the 3 year and 5 year total returns are approximately 7.8x and 11.1x respectively.

The company reports annual revenue of US$60.99b and net income of US$11.30b. Reported annual revenue growth shows a decline of 5.4%, while net income growth is slightly lower, down 0.6%.

Chubb’s operations are spread across several insurance and reinsurance segments. North America Commercial P&C Insurance contributes US$24.42b of revenue and Overseas General Insurance adds US$16.10b. North America Personal P&C Insurance and Agricultural Insurance contribute US$7.44b and US$3.03b respectively.

Life Insurance accounts for US$8.96b of revenue, while Global Reinsurance adds US$1.70b. Smaller line items such as segment adjustments, unallocated realized gains or losses, and market risk benefits gains or losses modestly offset the total.

See our latest analysis for Chubb.

Recent trading has been relatively steady, with a 1 day share price return of 3.7% and a year to date share price return of 5.2%. The 1 year total shareholder return of 12.5% suggests that most of the gains for long term holders have already come through rather than building rapidly in recent weeks.

If you are looking to cast the net wider beyond insurance, this could be a good moment to see what else is moving and check out 21 top founder-led companies

With Chubb’s recent returns, mixed growth figures and a market value of about US$122b, the key question is simple: is this stock still trading below its underlying worth, or is the market already pricing in future growth?

Most Popular Narrative: 6% Undervalued

Chubb's most followed valuation narrative pegs fair value at about $345.78 per share, a touch above the recent $326.27 close, which keeps the focus firmly on what is driving that gap.

Capital deployment through ongoing share repurchases (new $5b authorization), growing dividends, and selective M&A is creating upward pressure on earnings per share (EPS), while robust cash flow and capital position provide flexibility for further shareholder returns.

Growth in specialized insurance demand, such as cyber and high-net-worth personal lines, driven by macro trends (digitalization, greater risk exposures, climate-driven catastrophes), positions Chubb to leverage expertise and scale for above-industry-average topline and earnings growth.

Read the complete narrative.

Want to see what sits underneath that fair value call? The narrative leans on changing revenue mix, firmer profit margins, and a specific earnings multiple investors are being asked to accept. Curious which assumptions really carry the weight here and how sensitive the outcome is if they shift?

Result: Fair Value of $345.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, higher catastrophe losses and softer large account property pricing could pressure margins and earnings, which would challenge the current fair value narrative.

Find out about the key risks to this Chubb narrative.

Another Angle on Value

The narrative and analyst target suggest Chubb trades below fair value, but the P/E ratio tells a tighter story. Chubb sits at 11.2x earnings versus 10.9x for the US Insurance industry and a fair ratio of 10.4x, which points to some valuation risk if sentiment cools.

For a closer look at what the earnings multiples are implying compared with peers and that fair ratio the market could move towards, See what the numbers say about this price — find out in our valuation breakdown.

NYSE:CB P/E Ratio as at Jun 2026
NYSE:CB P/E Ratio as at Jun 2026

Next Steps

With mixed signals on value and sentiment, the key is to weigh the upside and the risks for yourself, then move quickly to assess the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at just one stock, you risk missing other solid opportunities, so use the tools available and regularly scan for fresh ideas that fit your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:CB

Chubb

Provides insurance and reinsurance products worldwide.

Proven track record with adequate balance sheet and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
37 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
59 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
21 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
19 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AE
ASML logo
Aequitas on ASML Holding ·

ASML Will Reign as the Kingpin of the Semiconductor Supply Chain

Fair Value:€1.87k16.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
FTNT logo
Aequitas on Fortinet ·

Fortinet, compounding Cyber Security Player.

Fair Value:US$116.8430.4% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
CSU logo
Aequitas on Constellation Software ·

Constellation Software: A Proven Serial Acquirer at a Discount

Fair Value:CA$3.72k28.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
70 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
70 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
TR
tripledub
GOOGL logo
tripledub on Alphabet ·

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.

Fair Value:US$23039.0% overvalued
92 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

0
|
0